🇺🇸 FDA
Patent

US 12213996

Methods of treating optic nerve diseases using neural progenitor cell growth factors

granted A61KA61K35/30A61K38/18

Quick answer

US patent 12213996 (Methods of treating optic nerve diseases using neural progenitor cell growth factors) held by REGENERATIVE RESEARCH FOUNDATION expires Mon Jan 30 2045 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
REGENERATIVE RESEARCH FOUNDATION
Grant date
Tue Feb 04 2025 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Jan 30 2045 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
17
CPC classes
A61K, A61K35/30, A61K38/18, A61K38/1825, A61K38/1841